After a median follow-up of @ months ( IQR @-@ ) , overall survival was significantly better with regorafenib than it was with placebo ( hazard ratio @ , @ % CI @-@ , one-sided p = @ ; median overall survival @ months -LSB- @ % CI @-@ -RSB- in the regorafenib group vs @ months -LSB- @-@ -RSB- in the placebo group ) .